We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

124 hedge funds and large institutions have $549M invested in Enanta Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 21

35% more capital invested

Capital invested by funds: $408M → $549M (+$141M)

12% more funds holding

Funds holding: 111 → 124 (+13)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 42

62% less call options, than puts

Call options by funds: $1.13M | Put options by funds: $2.97M

Holders
124
Holders Change
+13
Holders Change %
+11.71%
% of All Funds
3.31%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
36
Reduced
42
Closed
21
Calls
$1.13M
Puts
$2.97M
Net Calls
-$1.84M
Net Calls Change
-$857K

Top Buyers

1
ACM
Apex Capital Management
Ohio
+$24M
2
State Street
State Street
Massachusetts
+$17.8M
3
BFA
BlackRock Fund Advisors
California
+$11.5M
4
EAM
Eagle Asset Management
Florida
+$8.23M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.67M

Top Sellers

1
SAM
Senzar Asset Management
New York
-$23.4M
2
RCM
RA Capital Management
Massachusetts
-$9.89M
3
GC
Guggenheim Capital
Illinois
-$7.39M
4
Marshall Wace
Marshall Wace
United Kingdom
-$5.45M
5
NI
Numeric Investors
Massachusetts
-$4.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Stifel Financial
76
Stifel Financial
Missouri
$450K +$396K +8,840 New
Swiss National Bank
77
Swiss National Bank
Switzerland
$427K – – –
RhumbLine Advisers
78
RhumbLine Advisers
Massachusetts
$418K -$20.1K -450 -5%
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
$418K – – –
BG
80
BlackRock Group
United Kingdom
$413K -$265K -5,922 -42%
Wellington Management Group
81
Wellington Management Group
Massachusetts
$412K +$363K +8,100 New
Bank of America
82
Bank of America
North Carolina
$367K -$21.4K -479 -6%
GCP
83
GSA Capital Partners
United Kingdom
$366K -$716K -16,000 -69%
Royal Bank of Canada
84
Royal Bank of Canada
Ontario, Canada
$362K +$307K +6,857 +2,710%
Citigroup
85
Citigroup
New York
$356K +$251K +5,614 +409%
AL
86
Airain Ltd
Guernsey
$340K -$498K -11,127 -62%
Nomura Holdings
87
Nomura Holdings
Japan
$340K +$307K +6,859 New
AIG
88
American International Group
New York
$336K -$7.03K -157 -2%
California Public Employees Retirement System
89
California Public Employees Retirement System
California
$335K +$340K +7,600 New
PNC Financial Services Group
90
PNC Financial Services Group
Pennsylvania
$303K +$74.3K +1,659 +39%
Connor, Clark & Lunn Investment Management (CC&L)
91
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$270K -$188K -4,200 -44%
VOYA Investment Management
92
VOYA Investment Management
Georgia
$269K – – –
QIM
93
Quantitative Investment Management
Virginia
$264K +$233K +5,200 New
ICAS
94
Investors Capital Advisory Services
Massachusetts
$263K +$232K +5,190 New
Capital Fund Management (CFM)
95
Capital Fund Management (CFM)
France
$259K +$228K +5,100 New
DS
96
DRW Securities
Illinois
$254K +$224K +5,000 New
BKA
97
Brick & Kyle Associates
Pennsylvania
$245K +$216K +4,825 New
BNP Paribas Asset Management
98
BNP Paribas Asset Management
France
$244K +$214K +4,790 New
DAM
99
Doheny Asset Management
California
$221K +$195K +4,350 New
UBS Group
100
UBS Group
Switzerland
$221K +$195K +4,350 New
2 3
4
5 6

ENTA Hedge Fund Activity: Q4 2014 in Review

124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2014, worth a combined $549M — up 35% from $408M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ENTA positions and 21 closed out — a net gain of 14 holders — while 36 added to existing stakes and 42 trimmed.

The largest buyer was Apex Capital Management, adding an estimated $24M. The largest seller was Senzar Asset Management, cutting an estimated $23.4M.

  • 124 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2014, up from 111 in Q3 2014.
  • Funds reported $549M of Enanta Pharmaceuticals stock for Q4 2014, up 35% quarter-over-quarter.
  • 35 funds opened new Enanta Pharmaceuticals positions in Q4 2014 and 21 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2014 was Apex Capital Management, an estimated $24M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2014 was Senzar Asset Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q4 2014.